PAHC

SEC source: 0001104659-25-104520 · tm2529878-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 44,440

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.71 to $41.30.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-104520 · tm2529878-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 47,960

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.33 to $41.94.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-104520 · tm2529878-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 51,480

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.21 to $41.935. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-102227 · tm2529395-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 55,000

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.265 to $42.28.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-102227 · tm2529395-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 58,520

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.46.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-102227 · tm2529395-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 62,040

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $41.555. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-101314 · tm2529035-1_4seq1.xml · derivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,086,034

Underlying: Class A Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F5 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-101314 · tm2529035-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 73,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-101314 · tm2529035-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 23,899

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.59.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-101314 · tm2529035-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 39,974

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.07. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-095629 · tm2527686-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 40,674

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.635. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-092211 · tm2526522-1_4seq1.xml · derivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,136,034

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F4 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-092211 · tm2526522-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 61,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-092211 · tm2526522-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 31,338

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.51. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001410578-25-002185 · tm2525853-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 38,360

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.665 to $41.265.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001410578-25-002185 · tm2525853-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 41,880

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.23 to $41.39.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001410578-25-002185 · tm2525853-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 45,400

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.81. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-080274 · tm2523826-8_4seq1.xml · nonDerivative · entry 1

Miller Larry Lee · CIK 0001603584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,184

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.

SEC source: 0001104659-25-080273 · tm2523826-7_4seq1.xml · nonDerivative · entry 1

Weinstein Judith · CIK 0001982496 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,447

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.

SEC source: 0001104659-25-080272 · tm2523826-6_4seq1.xml · nonDerivative · entry 1

David Glenn · CIK 0001606256 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,845

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.

SEC source: 0001104659-25-080269 · tm2523826-5_4seq1.xml · nonDerivative · entry 1

BENDHEIM Jonathan · CIK 0001751891 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,268

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.

SEC source: 0001104659-25-080266 · tm2523826-4_4seq1.xml · nonDerivative · entry 1

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,964

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.

SEC source: 0001104659-25-080265 · tm2523826-3_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,320

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.

SEC source: 0001104659-25-080262 · tm2523826-2_4seq1.xml · nonDerivative · entry 1

Escudero Lisa Ann · CIK 0001701415 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,152

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.

SEC source: 0001104659-25-080257 · tm2523826-1_4seq1.xml · nonDerivative · entry 1

Andolino Anthony · CIK 0001733719 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,793

F1 · security: The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to the Reporting Person's continued employment through the applicable vesting date.

SEC source: 0001104659-25-017440 · tm257506-1_4seq1.xml · nonDerivative · entry 1

CORCORAN E THOMAS · CIK 0001191763 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.02 to $22.11. The Reporting Person undertakes to provide to the Issuer, any security holders of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within this range.

SEC source: 0001104659-25-011486 · tm256086-1_4seq1.xml · derivative · entry 2

David Glenn · CIK 0001606256 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,000

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. No shares of Class A Common Stock were transferred or sold upon the vesting of the RSUs listed in Table II and the reporting person will pay the related tax withholding obligations in cash.

F2 · derivative.exercise_date: On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

F3 · derivative.exercise_date: Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of Phibro Animal Health Corporation's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.

F2 · derivative.expiration_date: On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

F3 · derivative.expiration_date: Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of Phibro Animal Health Corporation's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.

SEC source: 0001104659-25-011486 · tm256086-1_4seq1.xml · nonDerivative · entry 1

David Glenn · CIK 0001606256 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. No shares of Class A Common Stock were transferred or sold upon the vesting of the RSUs listed in Table II and the reporting person will pay the related tax withholding obligations in cash.

SEC source: 0001104659-24-097763 · tm2423503-1_4seq1.xml · nonDerivative · entry 1

CORCORAN E THOMAS · CIK 0001191763 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.89 to $20.20. The Reporting Person undertakes to provide to the Issuer, any security holders of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within this range.

SEC source: 0001104659-24-013213 · tm245346-2_4seq1.xml · derivative · entry 1

David Glenn · CIK 0001606256 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Class A Common Stock · 300,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

F3 · derivative.exercise_date: Pursuant to the Award Agreement, (i) 150,000 RSUs will be subject to time vesting (collectively, the "Time Vesting RSUs") and will vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs will be subject to performance vesting (collectively, the "Performance Vesting RSUs") and will vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of Phibro Animal Health Corporation's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.

F3 · derivative.expiration_date: Pursuant to the Award Agreement, (i) 150,000 RSUs will be subject to time vesting (collectively, the "Time Vesting RSUs") and will vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs will be subject to performance vesting (collectively, the "Performance Vesting RSUs") and will vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of Phibro Animal Health Corporation's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.

F2 · derivative.underlying_shares: On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

F2 · balance_after: On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

SEC source: 0001104659-23-079131 · tm2320607-2_4seq1.xml · derivative · entry 1

Miller Larry Lee · CIK 0001603584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Class A Common Stock · 300,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A Common Stock.

F2 · shares: On July 5, 2023, the Compensation Committee approved the grant to the reporting person of 300,000 RSUs subject to performance-based vesting based solely on the Company's stock price.

F3 · derivative.exercise_date: The RSUs will vest on June 30, 2027, in increments of 10% (but no less than 20%) (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Company's closing stock price per share for each trading day in the 90 calendar day period ended June 30, 2027 (the "90-Day Average") from $20 to $60 and above, subject to the reporting person's continued employment on such date, and subject to earlier vesting upon certain qualifying termination events. None of the RSUs will vest if the 90-Day Average is below $20, and the maximum vesting percentage for the RSUs is 100% for achievement of a 90-Day Average of $60 or above. Vested shares will be delivered to the reporting person within 30 days after vesting, subject to later delivery in the event of certain trading blackout periods.

F3 · derivative.expiration_date: The RSUs will vest on June 30, 2027, in increments of 10% (but no less than 20%) (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Company's closing stock price per share for each trading day in the 90 calendar day period ended June 30, 2027 (the "90-Day Average") from $20 to $60 and above, subject to the reporting person's continued employment on such date, and subject to earlier vesting upon certain qualifying termination events. None of the RSUs will vest if the 90-Day Average is below $20, and the maximum vesting percentage for the RSUs is 100% for achievement of a 90-Day Average of $60 or above. Vested shares will be delivered to the reporting person within 30 days after vesting, subject to later delivery in the event of certain trading blackout periods.

F2 · derivative.underlying_shares: On July 5, 2023, the Compensation Committee approved the grant to the reporting person of 300,000 RSUs subject to performance-based vesting based solely on the Company's stock price.

F2 · balance_after: On July 5, 2023, the Compensation Committee approved the grant to the reporting person of 300,000 RSUs subject to performance-based vesting based solely on the Company's stock price.

SEC source: 0001104659-21-112162 · tm2126821d1_4.xml · nonDerivative · entry 1

CORCORAN E THOMAS · CIK 0001191763 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

SEC source: 0001104659-21-020033 · tm216079d1_4seq1.xml · nonDerivative · entry 2

Miller Larry Lee · CIK 0001603584 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.59 to $23.20, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001104659-21-020033 · tm216079d1_4seq1.xml · derivative · entry 3

Miller Larry Lee · CIK 0001603584 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 250,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represented a contingent right to receive one share of Class A Common Stock.

F4 · derivative.exercise_date: RSUs were granted on May 7, 2018, 50,000 RSUs vested on December 31, 2020 and 200,000 performance-based RSUs were cancelled for not meeting the performance requirement. Vested shares were delivered on February 8, 2021.

F4 · derivative.expiration_date: RSUs were granted on May 7, 2018, 50,000 RSUs vested on December 31, 2020 and 200,000 performance-based RSUs were cancelled for not meeting the performance requirement. Vested shares were delivered on February 8, 2021.

SEC source: 0001104659-21-020033 · tm216079d1_4seq1.xml · nonDerivative · entry 1

Miller Larry Lee · CIK 0001603584 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represented a contingent right to receive one share of Class A Common Stock.

SEC source: 0001144204-19-043491 · tv528900_form4.xml · nonDerivative · entry 1

CORCORAN E THOMAS · CIK 0001191763 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

SEC source: 0001144204-19-003872 · tv511990_4.xml · derivative · entry 9

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 2,390 shares

Expires 2019-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 6

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.04 to $31.30, inclusive.

SEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 5

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,390

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-003872 · tv511990_4.xml · derivative · entry 8

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,390

Underlying: Class A Common Stock · 4,890 shares

Expires 2019-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 4

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.08 to $31.73, inclusive.

SEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 3

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,890

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-003872 · tv511990_4.xml · derivative · entry 7

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,280

Underlying: Class A Common Stock · 2,500 shares

Expires 2019-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 2

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.19 to $32.08, inclusive.

SEC source: 0001144204-19-003872 · tv511990_4.xml · nonDerivative · entry 1

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-002703 · tv511485_4.xml · derivative · entry 10

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,780

Underlying: Class A Common Stock · 2,500 shares

Expires 2019-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 7

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.10, inclusive.

SEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 6

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-002703 · tv511485_4.xml · derivative · entry 9

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,280

Underlying: Class A Common Stock · 2,500 shares

Expires 2019-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

SEC source: 0001144204-19-002703 · tv511485_4.xml · nonDerivative · entry 5

Bendheim Daniel M · CIK 0001601576 · Director · Exec. VP, Corporate Strategy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.13 to $32.21, inclusive.